Clinical trial ELDERLY
Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicenter randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | EORTC |
| EudraCT Identifier | 2011-00634-232 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01597414 |
| Inclusion criteria | HER2+. Age Superior to 70 years old |
| Last update |